341 related articles for article (PubMed ID: 22621393)
1. JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer.
Lee YF; Miller LD; Chan XB; Black MA; Pang B; Ong CW; Salto-Tellez M; Liu ET; Desai KV
Breast Cancer Res; 2012 May; 14(3):R85. PubMed ID: 22621393
[TBL] [Abstract][Full Text] [Related]
2. JMJD6 induces HOTAIR, an oncogenic lincRNA, by physically interacting with its proximal promoter.
Biswas A; Shettar A; Mukherjee G; Kondaiah P; Desai KV
Biochem J; 2018 Jan; 475(1):355-371. PubMed ID: 29229759
[TBL] [Abstract][Full Text] [Related]
3. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE
Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402
[TBL] [Abstract][Full Text] [Related]
4. JMJD6 orchestrates a transcriptional program in favor of endocrine resistance in ER+ breast cancer cells.
Das P; Gupta A; Desai KV
Front Endocrinol (Lausanne); 2022; 13():1028616. PubMed ID: 36419768
[TBL] [Abstract][Full Text] [Related]
5. Both EZH2 and JMJD6 regulate cell cycle genes in breast cancer.
Biswas A; Mukherjee G; Kondaiah P; Desai KV
BMC Cancer; 2020 Nov; 20(1):1159. PubMed ID: 33246425
[TBL] [Abstract][Full Text] [Related]
6. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
[TBL] [Abstract][Full Text] [Related]
7. JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI.
Li LL; Xue AM; Li BX; Shen YW; Li YH; Luo CL; Zhang MC; Jiang JQ; Xu ZD; Xie JH; Zhao ZQ
Breast Cancer Res; 2014 May; 16(3):R56. PubMed ID: 24886710
[TBL] [Abstract][Full Text] [Related]
8. Role of JMJD6 in Breast Tumourigenesis.
Poulard C; Rambaud J; Lavergne E; Jacquemetton J; Renoir JM; Trédan O; Chabaud S; Treilleux I; Corbo L; Le Romancer M
PLoS One; 2015; 10(5):e0126181. PubMed ID: 25951181
[TBL] [Abstract][Full Text] [Related]
9. JMJD6 promotes melanoma carcinogenesis through regulation of the alternative splicing of PAK1, a key MAPK signaling component.
Liu X; Si W; Liu X; He L; Ren J; Yang Z; Yang J; Li W; Liu S; Pei F; Yang X; Sun L
Mol Cancer; 2017 Nov; 16(1):175. PubMed ID: 29187213
[TBL] [Abstract][Full Text] [Related]
10. Expression of quiescin sulfhydryl oxidase 1 is associated with a highly invasive phenotype and correlates with a poor prognosis in Luminal B breast cancer.
Katchman BA; Ocal IT; Cunliffe HE; Chang YH; Hostetter G; Watanabe A; LoBello J; Lake DF
Breast Cancer Res; 2013 Mar; 15(2):R28. PubMed ID: 23536962
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of JMJD6 expression reduces the proliferation, migration and invasion of neuroglioma stem cells.
Zhou DX; Zhou D; Zhan SQ; Wang P; Qin K; Gan W; Lin XF
Neoplasma; 2017; 64(5):700-708. PubMed ID: 28592121
[TBL] [Abstract][Full Text] [Related]
12. LncRNA ZFPM2-AS1 aggravates the malignant development of breast cancer via upregulating JMJD6.
Zhao YF; Li L; Li HJ; Yang FR; Liu ZK; Hu XW; Wang Q
Eur Rev Med Pharmacol Sci; 2020 Nov; 24(21):11139-11147. PubMed ID: 33215431
[TBL] [Abstract][Full Text] [Related]
13. MiR-770 inhibits tumorigenesis and EMT by targeting JMJD6 and regulating WNT/β-catenin pathway in non-small cell lung cancer.
Zhang Z; Yang Y; Zhang X
Life Sci; 2017 Nov; 188():163-171. PubMed ID: 28882645
[TBL] [Abstract][Full Text] [Related]
14. JMJD6 Licenses ERα-Dependent Enhancer and Coding Gene Activation by Modulating the Recruitment of the CARM1/MED12 Co-activator Complex.
Gao WW; Xiao RQ; Zhang WJ; Hu YR; Peng BL; Li WJ; He YH; Shen HF; Ding JC; Huang QX; Ye TY; Li Y; Liu ZY; Ding R; Rosenfeld MG; Liu W
Mol Cell; 2018 Apr; 70(2):340-357.e8. PubMed ID: 29628309
[TBL] [Abstract][Full Text] [Related]
15. JMJD6 promotes hepatocellular carcinoma carcinogenesis by targeting CDK4.
Wan J; Liu H; Yang L; Ma L; Liu J; Ming L
Int J Cancer; 2019 May; 144(10):2489-2500. PubMed ID: 30125344
[TBL] [Abstract][Full Text] [Related]
16. Histone demethylase JMJD6 regulates cellular migration and proliferation in adipose-derived mesenchymal stem cells.
Shen C; Quan Q; Yang C; Wen Y; Li H
Stem Cell Res Ther; 2018 Aug; 9(1):212. PubMed ID: 30092848
[TBL] [Abstract][Full Text] [Related]
17. High expression of JMJD6 predicts unfavorable survival in lung adenocarcinoma.
Zhang J; Ni SS; Zhao WL; Dong XC; Wang JL
Tumour Biol; 2013 Aug; 34(4):2397-401. PubMed ID: 23595221
[TBL] [Abstract][Full Text] [Related]
18. CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines.
Zabouo G; Imbert AM; Jacquemier J; Finetti P; Moreau T; Esterni B; Birnbaum D; Bertucci F; Chabannon C
Breast Cancer Res; 2009; 11(1):R1. PubMed ID: 19123925
[TBL] [Abstract][Full Text] [Related]
19. ShRNA-mediated gene silencing of MTA1 influenced on protein expression of ER alpha, MMP-9, CyclinD1 and invasiveness, proliferation in breast cancer cell lines MDA-MB-231 and MCF-7 in vitro.
Jiang Q; Zhang H; Zhang P
J Exp Clin Cancer Res; 2011 May; 30(1):60. PubMed ID: 21595884
[TBL] [Abstract][Full Text] [Related]
20. ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC.
Griffin NI; Sharma G; Zhao X; Mirza S; Srivastava S; Dave BJ; Aleskandarany M; Rakha E; Mohibi S; Band H; Band V
Breast Cancer Res; 2016 Nov; 18(1):113. PubMed ID: 27852327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
